Conference Coverage

Ozanimod Is Superior to Interferon in Relapsing-Remitting MS

Neurology Reviews. 2018 January;26(1):21

 

—Erik Greb

Suggested Reading

Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):373-381.

Sørensen PS. Ozanimod: a better or just another S1P receptor modulator? Lancet Neurol. 2016;15(4):345-347.

Pages

Recommended Reading

Does Concussion Increase the Risk of MS?
ICYMI Multiple Sclerosis
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
ICYMI Multiple Sclerosis
MS Treatment Decisions Based on Milestones That Matter
ICYMI Multiple Sclerosis
Fingolimod Reduces Annualized Relapse Rate in Pediatric MS
ICYMI Multiple Sclerosis
Siponimod Improves MRI Outcomes in Patients With Secondary Progressive MS
ICYMI Multiple Sclerosis
Interferon Beta May Reduce Mortality in MS
ICYMI Multiple Sclerosis
What Is the Prevalence of Truly Benign MS?
ICYMI Multiple Sclerosis
Oligoclonal Bands Could Be a Valuable Criterion for the Diagnosis of MS
ICYMI Multiple Sclerosis
Durable Improvements in Clinical Outcomes With Alemtuzumab: Seven-Year Follow-Up
ICYMI Multiple Sclerosis
Revised McDonald Criteria Allow Substitution for Dissemination in Time
ICYMI Multiple Sclerosis

Related Articles